

Date: 07.08.2025

To,
BSE Limited
The Compliance Department of Corporate Services,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Scrip Code: 531592

Subject: Outcome of the Meeting of Board of Directors held on Thursday, 07th August, 2025.

Dear Sir/ Madam,

With reference to the captioned subject and Pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that the Board of Directors of the Company at its meeting held on today, i.e. Thursday, 07th August, 2025, inter alia, considered and approved:

1. The Un-audited Standalone & Consolidated Financial Results of the Company for the quarter ended 30th June, 2025 along with Limited Review Report after these results are reviewed by the Audit Committee.

We further inform you that the Board Meeting commenced at 02:00 p.m. today and concluded at 02:50 p.m.

Kindly take the same on records for your perusal.

Thanking you,

Yours faithfully,

For and behalf of the Board of Director of,
Genpharmasec Limited

SOHAN
CHATURVEDI

Digitally signed by
SOHAN CHATURVEDI
Date: 2025.08.07
14:57:14 +05'30'



Mr. Sohan Chaturvedi
Whole time director & CFO
DIN- 09629728

Encl:

1. Un-Audited Standalone & Consolidated Financial Results for the quarter ended June 30, 2025.
2. Limited Review Reports.



Abhishek S Tiwari & Associates

CHARTERED ACCOUNTANTS

Office: G-2 Mukund Smruti, Ideal Park, Near Orange Hospital, Bhayander (East), Dist – Thane,
Maharashtra-401105 Mob 9029326651, Email: caabhishek2012@gmail.com

Independent Auditor’s Review Report on Standalone Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To
Board of Directors of
GENPHARMASEC LIMITED

We have reviewed the accompanying statement of unaudited standalone financial results (‘the Statement’) of GENPHARMASEC LIMITED, for the quarter ended 30th June, 2025, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including relevant circulars issued by the SEBI from time to time.

The Statement, which is the responsibility of the Company’s Management and approved by the Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (‘Ind AS 34’), prescribed under Section 133 of the Companies Act, 2013 (‘the Act’), SEBI Circular CIR/CFD/FAC/62/2016 dated 5 July 2016, (hereinafter referred to as ‘the SEBI Circular’), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, the SEBI Circular(s), and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Abhishek S Tiwari & Associates
Chartered Accountants
Firm Reg.No.141048W**

ABHISHEK
SUSHIL KUMAR
TIWARI
Digitally signed by
ABHISHEK SUSHIL
KUMAR TIWARI
Date: 2025.08.07
14:44:45 +05'30'

Abhishek Tiwari
Partner

M.No.155947

Place of signature: Mumbai

Date: 07.08.2025

UDIN- 25155947BMJBGC4582

GENPHARMASEC LIMITED				
Standalone Statement of unaudited financial results for the quarter ended 30th June, 2025				
(Amount in Lakhs)				
Particulars	Quarter Ended		Year Ended	
	30th June 2025	31st March 2025	30th June 2024	31st March 2025
	Unaudited	Audited	Unaudited	Audited
I. Revenue from operations	1,211.32	1,355.56	530.29	3,296.36
II. Other income	82.24	106.05	57.79	342.80
III. Total income (I + II)	1,293.55	1,461.61	588.08	3,639.16
IV. Expenses:				
(a) Cost of materials consumed	-	-	-	-
(b) Purchase of Stock-in-Trade	1,075.12	975.54	547.34	2,847.23
(c) Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(69.84)	395.76	(119.11)	66.92
(d) Employee benefit expense	21.19	17.66	17.29	66.81
(e) Finance costs	7.67	5.98	7.11	27.75
(f) Depreciation and amortization expense	4.31	3.98	0.49	13.31
(g) Other expenses	84.52	66.23	61.76	272.49
V. Total Expenses	1,122.97	1,465.16	514.88	3,294.51
VI. Profit before tax (III - V)	170.58	(3.55)	73.20	344.65
Tax expense:				
(1) Current tax	16.81	25.53	-	68.74
(2) Deferred Tax	(2.15)	(6.39)	(14.33)	29.03
VII. Total Tax Expense	14.66	19.13	(14.33)	97.77
VIII. Profit for the period (VI-VII)	155.92	(22.68)	58.87	246.88
Other Comprehensive Income/(Loss)				
(i) Items that will not be reclassified to Profit and Loss				
(a) Re-measurement gains/(losses) on defined benefit plans	-	-	-	-
(b) Income tax effect on above	-	-	-	-
(c) Equity instrument through other comprehensive income	14.26	(46.70)	22.42	(48.65)
(d) Income tax effect on above*	-	-	-	-
IX. Total Other Comprehensive Income / (Loss)	14.26	(46.70)	22.42	(48.65)
X. Total Comprehensive Income/(Loss) for the year (VIII + IX) (Comprising profit and other comprehensive income for the year)	170.18	(69.38)	81.29	198.22
Paid up Equity Share Capital (Face Value of Equity Share is Rs. 1/- each)	5,537.20	5,537.20	5,537.20	5,537.20
Other Equity				1,117.79
XI. Earning per equity share				
(a) Basic	0.03	(0.00)	0.01	0.04
(b) Diluted	0.03	(0.00)	0.01	0.04

*will be considered at the end of the financial year.

Notes:


- The Financial result were reviewed by the Audit Committee and approved by the Board of directors at their meeting on 07th August, 2025.
- The above result have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act 2013, and other recognized accounting practices and policies to the extent applicable.
- The audit report does not contain any qualification. The above financial result along with review report will be filed with the stock Exchange and will also be available on Company's website www.genpharmasec.com
- Segment Reporting has been annexed in Annexure 1.
- The certificate of CFO in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in respect of the above results has been placed before the Board of Directors.
- The figures of the last quarter of the previous year ended on 31st March 2025 are the balancing figures between the audited figures in respect of full financial year ended 31st March 2025 and published year to date reviewed figures upto third quarter ended 31st December 2024.
- The company has incorporated a new wholly owned subsidiary namely M/s. Clinigenome India Pvt Ltd to expand the business activities on 29th January 2024
- During the quarter ended 31st March, 2024; the company made investment in M/s. Derren Healthcare Pvt Ltd, (DHPL) as detailed hereunder:

The Company has entered into an Share Purchase Agreement (SPA) with DHPL and its promoters on 19th September 2023 for acquiring 70% shareholding of DHPL. The Company has also simultaneously entered into a Share Subscription Cum Shareholder's Agreement (SSSA) on the same day to and agreed to induct Rs. 5 Crores into DHPL and in turn, DHPL will allot 13,84,275 shares to the Company.

The Company made payment of Rs. 12,63,95,377/- to one of the Promoters, Mr. Vibhava Kumar Singh who is holding 70% shares in DHPL for purchase of 35,00,000 shares. The Company has also inducted Rs. 5 crore in DHPL for subscription of 13,84,275 shares. These payments represent full payment towards total acquisition of 70% shareholding in DHPL and additional shareholding as envisaged in SSSA.

The acquisition was estimated to be completed by 19th September 2024. However, due to pending execution of SPA & SSA, Genpharmasec Ltd, the company, has gained 'controlling interest' as on 25th July, 2025.
- The Board of Directors at its meeting held on 21st February 2024 allotted 27,68,59,850 shares to the Equity Shareholders of the Company through Right issue at issue price of Rs. 1.75 per equity Share (including a premium of Rs. 0.75 per equity Share).

PLACE : MUMBAI
Date : 07-08-2025



For and on behalf of the Board
GENPHARMASEC LIMITED

Sohan

SOHAN CHATURVEDI
(WHOLE TIME DIRECTOR
& CFO)
DIN:09629728

GENPHARMASEC LIMITED

"ANNEXURE - I"

Standalone statement of unaudited Segment-wise Revenue, Results, Assets and Liabilities for the Quarter ended 30th June, 2025

(Amount in Lakhs)

Particulars	Quarter Ended			Year Ended
	30th June 2025	31st March 2025	30th June 2024	31st March 2025
	Unaudited	Audited	Unaudited	Audited
Segment Revenue				
Pharmaceuticals	1,211.32	1,355.26	530.29	3,296.07
Trading in Securities	-	0.30	-	0.30
Total	1,211.32	1,355.56	530.29	3,296.36
Segment Results (Profit before tax and interest)				
Pharmaceuticals	178.25	5.38	79.55	372.55
Trading in Securities	-	(0.15)	-	(0.15)
Total	178.25	5.23	79.55	372.40
Less				
(i) Unallocated Finance Cost	(7.67)	(8.78)	(6.35)	(27.75)
(ii) Other unallocable expenditure net of unallocable income	-	-	-	-
(iii) Inter Segment Eliminations	-	-	-	-
Profit Before Tax	170.58	(3.55)	73.20	344.65
Segment Assets				
Pharmaceuticals	2,072.65	2,329.92	3,322.85	2,329.92
Trading in Securities	89.32	89.32	126.03	89.32
Un-Allocated	6,062.38	5,490.16	3,655.29	5,490.16
Total	8,224.35	7,909.40	7,104.17	7,909.40
Segment Liabilities				
Pharmaceuticals	968.78	939.72	245.07	939.72
Trading in Securities	-	-	-	-
Un-Allocated	430.39	314.69	6,859.10	314.69
Total	1,399.17	1,254.41	7,104.17	1,254.41

The company has reported segment information as per the Indian Accounting Standard 108 "Operating Segments" (IND AS 108).

For and on behalf of the Board
GENPHARMASEC LIMITED



Sohan

Sohan Chaturvedi
(WHOLE TIME DIRECTOR
& CFO)

DIN:09629728

PLACE : MUMBAI

Date : 07-08-2025



Abhishek S Tiwari & Associates

CHARTERED ACCOUNTANTS

Office: G-2 Mukund Smruti, Ideal Park, Near Orange Hospital, Bhayander (East), Dist – Thane,
Maharashtra-401105 Mob 9029326651, Email: caabhishek2012@gmail.com

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To
Board of Directors of
GENPHARMASEC LIMITED

Opinion

1. We have reviewed the accompanying Statement of unaudited Consolidated Financial Results (the Statement') of GENPHARMASEC LIMITED (the Holding Company') and its Subsidiary (the Holding Company and its Subsidiary together referred to as "the Group") (Refer annexure -1 for the list of entities included in the Statement) for the Quarter ended on 30th June, 2025, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including relevant circulars issued by the SEBI from time to time.
2. Based on our review conducted as below and based on the consideration of the review reports as referred to in paragraph 5 nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, the SEBI Circular(s), and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement

Basis for Opinion

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act'), SEBI Circular CIR/CFD/FAC/62/2016 dated 5 July 2016, (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.



Abhishek S Tiwari & Associates

CHARTERED ACCOUNTANTS

Office: G-2 Mukund Smruti, Ideal Park, Near Orange Hospital, Bhayander (East), Dist – Thane,
Maharashtra-401105 Mob 9029326651, Email: caabhishek2012@gmail.com

5. The accompanying financial result includes the separate financial results/financial information, in respect of M/s. Clinigenome India Private Limited subsidiary whose interim financial results have been reviewed by the separate auditor, which reflects total income of Rs 37.51 Lacs, total net loss after tax of Rs 34.40 Lacs and total comprehensive loss of Rs 34.40 Lacs for the quarter ended 30th June, 2025 have been furnished to us by the Holding Company's management. These financial information have not been reviewed by us.

Our conclusion on the Statement, and our report in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), read with SEBI Circular, in so far as it relates to the aforesaid subsidiaries, is based solely on such reviewed interim financial results.

Our conclusion is not modified in respect of this matter with respect to our reliance on the financial results certified by the Board of Directors.

6. The accompanying financial result includes the separate financial results/financial information, in respect of M/s. Genpharmasec Middle East DMCC subsidiary whose interim financial results have not been reviewed by us, which reflects total revenue of - Nil, total net profit after tax of - Nil and total comprehensive profit of - Nil for the quarter ended 30th June, 2025 have been furnished to us by the Holding Company's management. In our opinion and according to the information and explanations given to us by the Board of Directors, these standalone financial results/financial informations are not material to the Group.

Our conclusion on the Statement, and our report in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), read with SEBI Circular, in so far as it relates to the aforesaid subsidiaries, is based solely on such unreviewed interim financial results.

Our conclusion is not modified in respect of this matter with respect to our reliance on the financial results certified by the Board of Directors.

For Abhishek S Tiwari & Associates
Chartered Accountants
Firm Reg.No.141048W

ABHISHEK
SUSHIL KUMAR
TIWARI
TIWARI

Digitally signed by
ABHISHEK SUSHIL KUMAR
TIWARI
Date: 2025.08.07 14:50:39
+05'30'

Abhishek Tiwari
Partner

M.No.155947

Place of signature: Mumbai

Date: 07.08.2025

UDIN- 25155947BMJBGD8893



Abhishek S Tiwari & Associates

CHARTERED ACCOUNTANTS

Office: G-2 Mukund Smruti, Ideal Park, Near Orange Hospital, Bhayander (East), Dist – Thane,
Maharashtra- 401105 Mob 9029326651, Email: caabhishek2012@gmail.com

Independent Auditor’s Review Report on Consolidated Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont’d)

Annexure -1

List of entities included in the statement

Sr.No.	Name of the entity	Nature of relationship
1	Clingenome India Private Limited	100 % Subsidiary
2	Genpharmasec Middle East DMCC	52 % Subsidiary

ABHISHEK
SUSHIL KUMAR
TIWARI

Digitally signed by
ABHISHEK SUSHIL
KUMAR TIWARI
Date: 2025.08.07
14:50:47 +05'30'

GENPHARMASEC LIMITED				
Consolidated Statement of unaudited financial results for the quarter ended 30th June, 2025				
Particulars	Quarter Ended			Year Ended
	30th June 2025	31st March 2025	30th June 2024	31st March 2025
	Unaudited	Audited	Unaudited	Audited
I. Revenue from operations	1,204.32	1,400.97	519.50	3,372.18
II. Other income	69.48	93.68	56.70	306.22
III. Total Income (I + II)	1,273.80	1,494.65	576.20	3,678.40
IV. Expenses:				
(a) Cost of materials consumed	12.86	37.94	-	87.21
(b) Purchase of Stock-in-Trade	1,075.12	949.49	567.49	2,806.72
(c) Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(104.59)	408.86	(152.06)	60.90
(d) Employee benefit expense	34.96	31.03	17.58	98.87
(e) Financial costs	12.26	10.64	10.19	43.48
(f) Depreciation and amortization expense	26.59	25.65	15.60	81.15
(g) Other expenses	92.00	73.63	68.68	312.05
V. Total Expenses	1,149.19	1,537.23	527.50	3,490.38
VI. Profit before tax (III - V)	124.61	(42.58)	48.70	188.02
Tax expense:				
(1) Current tax	16.81	25.53	-	68.74
(2) Deferred Tax	(13.72)	(10.04)	(20.02)	(3.84)
(3) Prior Period Tax	-	-	-	-
VII. Total Tax Expense	3.09	15.49	(20.02)	64.90
VIII. Profit/(Loss) for the period (VI-VII)	121.52	(27.09)	28.68	123.12
Other Comprehensive Income/(Loss)				
(i) Items that will not be reclassified to Profit and Loss				
(a) Re-measurement gains/(losses) on defined benefit plans	-	-	-	-
(b) Income tax effect on above	-	-	-	-
(c) Equity instrument through other comprehensive income	14.26	(46.69)	22.42	(48.65)
(d) Income tax effect on above*	-	-	-	-
IX. Total Other Comprehensive Income / (Loss)	14.26	(46.69)	22.42	(48.65)
X. Total Comprehensive Income/(Loss) for the year (VIII + IX) (Comprising profit and other comprehensive income for the year)	135.78	(73.79)	51.10	74.47
Profit/(Loss) Attributable to Parent	135.79	(73.79)	51.39	76.79
Profit/(Loss) Attributable to Non-Controlling Interest	(0.00)	(0.00)	(0.29)	(2.32)
Paid up Equity Share Capital (Face Value of Equity Share is Rs. 1/- each)	5,537.20	5,537.20	5,537.20	5,537.20
Other Equity	-	-	-	990.77
XI. Earning per equity share				
(a) Basic	0.02	(0.01)	0.01	0.01
(b) Diluted	0.02	(0.01)	0.01	0.01

*will be considered at the end of the financial year.

Notes:

- The Consolidated financial result were reviewed by the Audit Committee and approved by the Board of directors at their meeting on 7th August , 2025.
- The above result have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act 2013, and other recognized accounting practices and policies to the extent applicable.
- The audit report does not contain any qualification. The above consolidated financial result along with review report will be filed with the stock Exchange and will also be available on Company's website www.genpharmasec.com
- Segment Reporting has been annexed in Annexure 1.
- The certificate of CFO in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in respect of the above results has been placed before the Board of Directors.
- The figures of the last quarter of the previous year ended on 31st March 2025 are the balancing figures between the audited figures in respect of full financial year ended 31st March 2025 and published year to date reviewed figures upto third quarter ended 31st December 2024.
- The company has incorporated a new wholly owned subsidiary namely M/s. Clinigenome India Pvt Ltd' to expand the business activities on 29th January 2024
- During the quarter ended 31st March, 2024; the company made investment in M/s. Derren Healthcare Pvt Ltd, (DHPL) as detailed hereunder:

The Company has entered into an Share Purchase Agreement (SPA) with DHPL and its promoters on 19th September 2023 for acquiring 70% shareholding of DHPL. The Company has also simultaneously entered into a Share Subscription Cum Shareholder's Agreement' (SSSA) on the same day to and agreed to induct Rs. 5 Crores into DHPL and in turn, DHPL will allot 13,84,275 shares to the Company.
The Company made payment of Rs. 12,63,95,377/- to one of the Promoters, Mr. Vibhava Kumar Singh who is holding 70% shares in DHPL for purchase of 35,00,000 shares. The acquisition was estimated to be completed by 19th September 2024. However, due to pending execution of SPA & SSA, Genpharmasec Ltd, the company, has gained 'controlling interest' as on 25th July, 2025
- The Board of Directors at its meeting held on 21st February 2024 allotted 27,68,59,850 shares to the Equity Shareholders of the Company through Right issue at issue price of Rs. 1.75 per equity Share (including a premium of Rs. 0.75 per equity Share).

PLACE : MUMBAI
Date : 07-08-2025



For and on behalf of the Board
GENPHARMASEC LIMITED

Sohan

Sohan Chaturvedi
(WHOLE TIME DIRECTOR
& CFO)
DIN:09629728

GENPHARMASEC LIMITED
"ANNEXURE - I"

Consolidated Statement of unaudited Segment-wise Revenue, Results, Assets and Liabilities for the quarter ended 30th June, 2025

Particulars	Quarter Ended			Year Ended
	30th June 2025	31st March 2025	30th June 2024	31st March 2025
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
Segment Revenue				
Pharmaceuticals	1,167.09	1,329.21	515.84	3,255.56
Trading in Securities	-	0.30	-	0.30
Laboratory Testing	37.24	71.46	3.66	116.32
Total Revenue	1,204.32	1,400.97	519.50	3,372.18
Segment Results (Profit before tax and interest)				
Pharmaceuticals	178.25	2.58	80.36	372.55
Trading in Securities	-	(0.15)	-	(0.15)
Laboratory Testing	(41.38)	(34.38)	(21.47)	(136.09)
Unallocable	-	0.00	-	(4.81)
Total	136.87	(31.94)	58.89	231.51
Less				
(i) Finance Cost	(12.26)	(10.64)	(10.19)	(43.48)
(ii) Other unallocable expenditure net of unallocable income	-	-	-	-
(iii) Inter Segment Eliminations	-	-	-	-
Profit Before Tax	124.61	(42.58)	48.70	188.02
Segment Assets				
Pharmaceuticals	2,023.11	2,329.91	3,273.41	2,329.91
Trading in Securities	89.32	89.32	126.03	89.32
Laboratory Testing	884.47	880.59	615.42	880.59
Un-Allocated	5,279.42	4,689.40	3,275.01	4,689.40
Total	8,276.32	7,989.22	7,289.87	7,989.22
Segment Liabilities				
Pharmaceuticals	968.78	1,365.17	245.07	1,365.17
Trading in Securities	-	-	-	-
Laboratory Testing	211.08	96.09	185.70	96.09
Un-Allocated	432.71	-	6,859.10	-
Total	1,612.57	1,461.26	7,289.87	1,461.26

The company has reported segment information as per the Indian Accounting Standard 108 "Operating Segments" (IND AS 108).



For and on behalf of the Board
GENPHARMASEC LIMITED

Sohan

Sohan Chaturvedi
(WHOLE TIME DIRECTOR
& CFO)
DIN:09629728

PLACE : MUMBAI
Date : 07-08-2025